PD-L1 expression and tumor mutational burden are common predictors of the response to anti-PD-1/PD-L1 therapy in lung cancer, but other factors, such as tumor-specific genes, dMMR/MSI, and the gut microbiome, also show promise as predictive biomarkers. The gene discussed is PDCD1; the disease is neoplasm.